You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Boehringer Ingelheim
Dow
Baxter
Colorcon

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 9,161,988

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,161,988
Title:Multimeric peptide conjugates and uses thereof
Abstract: The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases.
Inventor(s): Castaigne; Jean-Paul (Mont-Royal, CA), Demeule; Michel (Beaconsfield, CA), Che; Christian (Longueuil, CA), Thiot; Carine (Montreal, CA), Gagnon; Catherine (Montreal-Nord, CA), Lawrence; Betty (Bolton, CA)
Assignee: Angiochem Inc. (Montreal, CA)
Application Number:13/382,069
Patent Claims:see list of patent claims

Details for Patent 9,161,988

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Angiochem Inc. (Montreal, CA) 2029-07-02 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Angiochem Inc. (Montreal, CA) 2029-07-02 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Angiochem Inc. (Montreal, CA) 2029-07-02 RX Orphan search
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin VIAL;SINGLE-DOSE 761060 001 2018-04-09   Start Trial Angiochem Inc. (Montreal, CA) 2029-07-02 RX Orphan search
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Angiochem Inc. (Montreal, CA) 2029-07-02 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial Angiochem Inc. (Montreal, CA) 2029-07-02 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial Angiochem Inc. (Montreal, CA) 2029-07-02 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Baxter
Harvard Business School
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.